(3S,4R)-4-(4-氟苯基)-3-羟基甲基哌啶-1-羧酸苄酯 | 392328-26-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (3S,4R)-4-(4-氟苯基)-3-羟基甲基哌啶-1-羧酸苄酯
• 英文名称: (3S,4R)-(-)-N-benzyloxycarbonyl-4-(4'-fluorophenyl)-3-hydroxymethylpiperidine
• 英文别名: (3S,4R)-trans-1-benzyloxycarbonyl-4-(4-fluorophenyl)-3-hydroxymethylpiperidine；(3S,4R)-trans-N-benzyloxycarbonyl-4-(4-fluorophenyl)-3-hydroxymethylpiperidine；(3S,4R)-benzyl 4-(4-fluorophenyl)-3-(hydroxymethyl)piperidine-1-carboxylate；(3S,4R)-(-)-N-benzyloxycarbonyl-4-(4-fluorophenyl)-3-hydroxymethylpiperidine；benzyl (3S,4R)-4-(4-fluorophenyl)-3-(hydroxymethyl)piperidine-1-carboxylate
• CAS: 392328-26-6
• 化学式: C₂₀H₂₂FNO₃
• 分子量: 343.398
• InChiKey: WWQGNHZOLBIUME-HKUYNNGSSA-N

物化性质

• 沸点：
  490.6±45.0 °C(Predicted)
• 密度：
  1.214±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3S,4R)-4-(4-氟苯基)-3-羟基甲基哌啶-1-羧酸苄酯 在 palladium on activated charcoal 氢气 、 sodium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 25.0h， 生成 (3S,4r)-1-boc-3-羟基甲基-4-(4-氟苯基)-哌啶
  参考文献：
  名称：

  Enzymatic Resolution of trans-4-(4‘-Fluorophenyl)-3-hydroxymethylpiperidines, Key Intermediates in the Synthesis of (−)-Paroxetine

  摘要：

  Two Candida antarctica lipases catalyze the enantioselective acylation of N-substituted trans-4(4'-fluorophenyl)-3-hydroxymethylpiperidines in organic solvents. These two lipases show opposite stereochemical preference in these processes. Both enantiomers can be obtained in their optically pure forms. The (3S,4R) isomer, is an intermediate for the synthesis of (-)-Paroxetine.

  DOI：

  10.1021/jo010809+
• 作为产物：
  描述：

  (3S,4R)-(-)-3-acetyloxymethyl-N-benzyloxycarbonyl-4-(4'-fluorophenyl)piperidine 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 (3S,4R)-4-(4-氟苯基)-3-羟基甲基哌啶-1-羧酸苄酯
  参考文献：
  名称：

  Enzymatic Resolution of trans-4-(4‘-Fluorophenyl)-3-hydroxymethylpiperidines, Key Intermediates in the Synthesis of (−)-Paroxetine

  摘要：

  Two Candida antarctica lipases catalyze the enantioselective acylation of N-substituted trans-4(4'-fluorophenyl)-3-hydroxymethylpiperidines in organic solvents. These two lipases show opposite stereochemical preference in these processes. Both enantiomers can be obtained in their optically pure forms. The (3S,4R) isomer, is an intermediate for the synthesis of (-)-Paroxetine.

  DOI：

  10.1021/jo010809+

文献信息

• Optically pure paroxetine precursors
  申请人：Astur Pharma

  公开号：US20030018048A1

  公开（公告）日：2003-01-23

  A biocatalytic process to obtain optically enriched derivatives of trans-4-(4-fluorophenyl)-3-hydroxymethylpiperidines, based on the enzymatic resolution of racemic precursors of formula III (where R 3 is preferably phenyl or benzyl) by acylation of the hydroxyl group. Depending on the enzyme and the reaction conditions, either of the two enantiomers may be obtained with high enantiomeric purity. These compounds are important intermediates in the synthesis of the paroxetine anti-depressive agent. 1

  一种生物催化过程，用于获取光学纯度富集的trans-4-(4-氟苯基)-3-羟甲基哌啶衍生物，基于通过羟基酰化酶解racemic配体III（其中R3最好是苯基或苄基）获得。根据酶和反应条件，可以获得两个对映体之一，具有高对映纯度。这些化合物是合成帕罗西汀抗抑郁剂的重要中间体。1
• Process for preparing a piperidine derivative
  申请人：Sumika Fine Chemicals Co., Ltd.

  公开号：US20030144519A1

  公开（公告）日：2003-07-31

  A piperidine derivative, which can be used as an intermediate for pharmaceuticals such as paroxetine useful as antidepressants, represented by the general formula (I): 1 wherein R 1 is hydrogen atom, benzyloxycarbonyl group or tert-butoxycarbonyl group; R 2 is hydroxymethyl group, an alkylsulfonyloxymethyl group having an alkyl moiety of 1 to 2 carbon atoms, phenylsulfonyloxymethyl group which may have methyl group at the 4-position, (3,4-methylenedioxyphenyl)oxymethyl group, carboxyl group or —CO 2 R 7 group in which R 7 is an alkyl group having 1 to 5 carbon atoms, and Z is methylene group or carbonyl group, with proviso that, (A) when R 1 is benzyloxycarbonyl group or tert-butoxycarbonyl group, then R 2 is hydroxymethyl group, an alkylsulfonyloxymethyl group having an alkyl moiety of 1 to 2 carbon atoms, phenylsulfonyloxymethyl group which may have methyl group at the 4-position or (3,4-methylenedioxyphenyl)oxymethyl group, and Z is methylene group; or (B) when R 1 is hydrogen atom and Z is carbonyl group, then R 2 is carboxyl group or —CO 2 R 7 group (R 7 is as defined above); or (C) when R 1 is hydrogen atom and Z is methylene group, then R 2 is hydroxymethyl group

  一种哌啶衍生物，可用作如帕罗西汀等抗抑郁药物的中间体，由通式（I）表示：其中R1为氢原子，苄氧羰基基团或叔丁氧羰基基团；R2为羟甲基基团，具有1至2个碳原子的烷基磺酰氧甲基基团，可能在4位具有甲基基团的苯基磺酰氧甲基基团，（3,4-亚甲二氧基苯基）氧甲基基团，羧基或CO2R7基团，其中R7为具有1至5个碳原子的烷基基团，Z为亚甲基或羰基基团，但有附加条件，即（A）当R1为苄氧羰基基团或叔丁氧羰基基团时，R2为羟甲基基团，具有1至2个碳原子的烷基磺酰氧甲基基团，可能在4位具有甲基基团的苯基磺酰氧甲基基团或（3,4-亚甲二氧基苯基）氧甲基基团，而Z为亚甲基；或（B）当R1为氢原子且Z为羰基基团时，R2为羧基或CO2R7基团（其中R7如上所定义）；或（C）当R1为氢原子且Z为亚甲基时，R2为羟甲基基团。
• NOVEL BENZO[D][1,3]-DIOXOL DERIVATIVES
  申请人：Tung Roger

  公开号：US20080033011A1

  公开（公告）日：2008-02-07

  The present invention relates to an isotopologue of paroxetine substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to paroxetine. They may also be used to accurately determine the concentration of paroxetine in biological fluids and to determine metabolic patterns of paroxetine and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.

  本发明涉及一种取代苯并二氧戊环环上亚甲基碳上的氘代帕罗西汀同位素。本发明的同位素是选择性血清素再摄取抑制剂(SSRIs)，与帕罗西汀相比具有独特的生物制药和代谢特性。它们还可以用于准确测定生物液体中帕罗西汀的浓度以及确定帕罗西汀及其同位素的代谢模式。本发明还提供了包含这些氘代同位素的组合物和治疗对增加神经元血清素传递敏感的疾病和状况的方法，单独或与其他药物联合使用。
• Novel benzo[D][1,3]-dioxol derivatives
  申请人：Tung Roger

  公开号：US20070191432A1

  公开（公告）日：2007-08-16

  The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.

  本发明涉及一种在苯并二氧杂环环的亚甲基碳上取代氘的化合物1的同位素。本发明的同位素是选择性血清素再摄取抑制剂(SSRI)，与化合物1相比具有独特的生物制药和代谢特性。它们还可以用于准确确定生物液中化合物1的浓度，并确定化合物1及其同位素的代谢模式。本发明还提供了包含这些氘同位素的组合物以及治疗对增加神经元血清素传递敏感的疾病和病症的方法，单独或与其他药物联合使用。
• Novel benzo[d][1,3]-dioxol derivatives
  申请人：Tung Roger

  公开号：US20080287495A1

  公开（公告）日：2008-11-20

  The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.

  本发明涉及一种在苯二氧杂环环的亚甲基碳上用氘取代的化合物1的同位素。本发明的同位素选择性地抑制5-羟色胺再摄取，具有与化合物1相比独特的生物制药和代谢特性。它们还可用于准确测定生物液体中化合物1的浓度，并确定化合物1及其同位素的代谢模式。本发明还提供了包含这些氘同位素的组合物和治疗对增加神经元5-羟色胺传递敏感的疾病和病症的方法，单独或与其他药物联合使用。